Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 164 participants.

Also called NCT01879319

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 164 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01879319
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
Not reported
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01879319. Randomized; no masking; primary purpose treatment. Start 2013-07-11 (actual); primary completion 2013-11-15 (actual). Results posted on 2015-12-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen
Condition
Primary Hypercholesterolemia
Condition
Mixed Dyslipidemia
Intervention (Biological)
Evolocumab AMD
Intervention (Biological)
Evolocumab AI/pen
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct01879319
Content hash
59beeaae2e6176ef4a666d2d4da9b1c45358d90d98cc7f94b24e6f86e6a07745